Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dermacyd Breeze Pocket BR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd Breeze Pocket BR (Lactic Acid) |
| Name | Type | Description |
|---|---|---|
| Dermacyd Breeze Pocket BR (Lactic Acid) | DRUG | Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days |
Inclusion criteria: * Integral skin test in the region; * To use products of the same category; Exclusion criteria: * Lactation or gestation; * Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs; * Cutaneous disease (local or spread) in the evaluation area; * Pathology which may...
Dermacyd Breeze Pocket BR is a small molecule product used for hygiene purposes. It is being developed by Sanofi and is currently in Phase 3 clinical development. The product contains lactic acid and is intended for female use, as the clinical trial enrolled female participants aged 18 years and older.
Dermacyd Breeze Pocket BR is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The product is currently in Phase 3 clinical development for hygiene indications.
Dermacyd Breeze Pocket BR is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. The product is being studied for hygiene purposes, and one Phase 3 clinical trial has been completed.
Dermacyd Breeze Pocket BR has one completed clinical trial registered under NCT00793026, titled "Dermacyd Breeze Pocket BR (Lactic Acid) - Acceptability." This Phase 3 trial enrolled 30 female participants in Brazil and evaluated the product's acceptability for hygiene use.
Dermacyd Breeze Pocket BR contains lactic acid as its active ingredient. The clinical trial title refers to it as "Dermacyd Breeze Pocket BR (Lactic Acid)," indicating that lactic acid is a key component of the product. It is being developed for hygiene purposes.